

Referate:

- Dr. Shahrokh **Shariat**: Early cystectomy in high-risk NMIBC: A standard?
- Dr. Shahrokh **Shariat**: Should we sequence all urothelial cancer patients?
- Dr. Shahrokh **Shariat**: Cancer de la prostate métastatique hormono-sensible.
- Dr. Shahrokh **Shariat**: Cancer de la prostate métastatique résistant à la castration.
- Dr. Shahrokh **Shariat**: Rôle de la thérapie locale dans le cancer métastatique de la prostate.
- Dr. Shahrokh **Shariat**: Modern Management of Upper Tract Urothelial Carcinoma.
- Dr. Shahrokh **Shariat**: BCG unresponsive non uscle invasive bladder cancer
- Dr. Shahrokh **Shariat**: Tips for a successful career as a physician researcher.
- Dr. Shahrokh **Shariat**: Role local therapy for hormone sensitive metastatic prostate cancer.
- Dr. Shahrokh **Shariat**: Lokale Therapie fuer metastastisches Prostatakarzinom.
- Dr. Shahrokh **Shariat**: Kidney Sparing in upper tract urothelial carcinoma.
- Dr. Shahrokh **Shariat**: Prostatakarzinom.
- Dr. Julian **Veser**: Viele Wege ein Ziel: Steinfreiheit.

Publikationen:

Urologic Oncology, (Editors: Axel S. Merseburger, Maximilian Burger), Springer Verlag

- Francesco Soria, David **D'Andrea**, Kilian **Gust** und Shahrokh F. **Shariat**: Epidemiology and Sociocultural Differences for Bladder Cancer, S. 291 – 302.
- David **D'Andrea**, Fred Witjes, Francesco Soria und Shahrokh F. **Shariat**: Urothelial Carcinoma In Situ and Treatment of Bacillus Calmette-Guérin Failures, S. 337 – 350.
- Helen Davis Bondarenko, Raisa S. Pompe, Emanuele Zaffuto, Shahrokh F. **Shariat** und Pierre I. Karakiewicz: Prognostic and Predictive Markers, and Stratification Tables, for the Detection and Treatment of Renal Cell Carcinoma, S. 511 – 528.

Peer-review (kleine Auswahl):

1. Differential prognostic impact of different Gleason patterns in grade group 4 in radical prostatectomy specimens.
Mori K, Sharma V, Comperat EM, Sato S, **Laukhtina E**, **Schuetfort VM**, **Pradere B**, Parizi MK, Karakiewicz PI, Egawa S, Tilki D, Boorjian SA, **Shariat SF**. Eur J Surg Oncol. 2020 Dec 24;S0748-7983(20)31235-X. doi: 10.1016/j.ejso.2020.12.014. Online ahead of print.
PMID: 33371950
2. Evaluation of the New American Urological Association Guidelines Risk Classification for Hematuria.
Woldu SL, Ng CK, Loo RK, Slezak JM, Jacobsen SJ, Tan WS, Kelly JD, Lough T, Darling D, van Kessel KEM, de Jong JJ, van Criekinge W, **Shariat SF**, Hiar A, Brown S, Boorjian SA, Barocas DA, Svatek RS, Lotan Y. J Urol. 2020 Dec 24;101097JU0000000000001550. doi: 10.1097/JU.0000000000001550. Online ahead of print.
PMID: 33356483
3. Supervised machine learning enables non-invasive lesion characterization in primary prostate cancer with [⁶⁸Ga]Ga-PSMA-11 PET/MRI.
Papp L, Spielvogel CP, **Grubmüller B**, Grahovac M, Krajnc D, Ecsedi B, Sareshgi RAM, Mohamad D, Hamboeck M, Rausch I, Mitterhauser M, Wadsak W, Haug AR, Kenner L, Mazal P, Susani M, Hartenbach S, Baltzer P, Helbich TH, **Kramer G**, **Shariat SF**, Beyer T, Hartenbach M, Hacker M. Eur J Nucl Med Mol Imaging. 2020 Dec 19. doi: 10.1007/s00259-020-05140-y. Online

ahead of print.
PMID: 33341915

4. Contemporary rates and predictors of open conversion during minimally invasive partial nephrectomy for kidney cancer.
Luzzago S, Rosiello G, Pecoraro A, Deuker M, Stolzenbach F, Mistretta FA, Tian Z, Musi G, Montanari E, **Shariat SF**, Saad F, Briganti A, de Cobelli O, Karakiewicz PI. *Surg Oncol*. 2021 Mar;36:131-137. doi: 10.1016/j.suronc.2020.12.004. Epub 2020 Dec 11.
PMID: 33401103
5. Requirement of DNMT1 to orchestrate epigenomic reprogramming for NPM-ALK-driven lymphomagenesis.
Redl E, Sheibani-Tezerji R, Cardona CJ, Hamminger P, Timelthaler G, **Hassler MR**, Zrimšek M, Lagger S, Dillinger T, Hofbauer L, Draganić K, Tiefenbacher A, Kothmayer M, Dietz CH, Ramsahoye BH, Kenner L, Bock C, Seiser C, Ellmeier W, Schweikert G, Egger G. *Life Sci Alliance*. 2020 Dec 11;4(2):e202000794. doi: 10.26508/lsa.202000794. Print 2021 Feb.
PMID: 33310759
6. Association of Processed Meats and Alcohol Consumption with Renal Cell Carcinoma: A Worldwide Population-Based Study.
Ziouziou I, **Shariat SF**, Ajdi F, Khabbal Y. *Nutr Cancer*. 2020 Dec 7:1-6. doi: 10.1080/01635581.2020.1856388. Online ahead of print.
PMID: 33283531
7. Visibility of significant prostate cancer on multiparametric magnetic resonance imaging (MRI)-do we still need contrast media?
Huebner NA, Korn S, Resch I, Grubmüller B, Gross T, Gale R, **Kramer G**, Poetsch N, Clauser P, Haitel A, **Fajkovic H**, **Shariat SF**, Baltzer PA. *Eur Radiol*. 2020 Dec 2. doi: 10.1007/s00330-020-07494-1. Online ahead of print.
PMID: 33263793
8. Association of erectile dysfunction and cardiovascular disease: an umbrella review of systematic reviews and meta-analyses.
Mostafaei H, **Mori K**, Hajebrahimi S, **Abufaraj M**, Karakiewicz PI, **Shariat SF**. *BJU Int*. 2020 Dec 1. doi: 10.1111/bju.15313. Online ahead of print.
PMID: 33260254
9. [Stone therapy-use and limitations of the guidelines].
Seitz C, Türk C, Neisius A. *Urologe A*. 2020 Dec;59(12):1498-1503. doi: 10.1007/s00120-020-01394-4.
PMID: 33237370
10. Clinical Impact and Statistical Significance of Multiparametric Magnetic Resonance Imaging for Local Staging of Prostate Cancer.
Huebner NA, **Shariat SF**. *Eur Urol*. 2021 Feb;79(2):186-187. doi: 10.1016/j.eururo.2020.11.002. Epub 2020 Nov 24.
PMID: 33246667

11. Impact of Preoperative Serum Albumin-Globulin Ratio on Disease Outcome After Radical Cystectomy for Urothelial Carcinoma of the Bladder.
Schuetfort VM, D Andrea D, Quhal F, Mostafaei H, Laukhtina E, Mori K, Sari Motlagh R, Rink M, Abufaraj M, Karakiewicz PI, Luzzago S, Rouprêt M, Chlosta P, Babjuk M, Deuker M, Moschini M, Shariat SF, Pradere B.Urol Oncol. 2020 Nov 11:S1078-1439(20)30574-3. doi: 10.1016/j.urolonc.2020.11.005. Online ahead of print.
PMID: 33189530
12. Prognostic factors in patients with small renal masses: a comparison between <2 vs. 2.1-4 cm renal cell carcinomas.
Rosiello G, Pecoraro A, Luzzago S, Deuker M, Stolzenbach LF, Tian Z, Larcher A, Capitanio U, Montorsi F, **Shariat SF**, Kapoor A, Saad F, Briganti A, Karakiewicz PI.Cancer Causes Control. 2021 Feb;32(2):119-126. doi: 10.1007/s10552-020-01364-3. Epub 2020 Nov 9.
PMID: 33169306
13. The Predictive Value of Programmed Death Ligand 1 in Patients with Metastatic Renal Cell Carcinoma Treated with Immune-checkpoint Inhibitors: A Systematic Review and Meta-analysis.
Mori K, Abufaraj M, Mostafaei H, Quhal F, Fajkovic H, Remzi M, Karakiewicz PI, Egawa S, Schmidinger M, Shariat SF, Gust KM.Eur Urol. 2020 Nov 7:S0302-2838(20)30783-1. doi: 10.1016/j.eururo.2020.10.006. Online ahead of print.
PMID: 33172722
14. Association of Prostate Cancer with Nuts, Seeds, Alcohol and Processed Meats: A Worldwide Population-Based Study.
Ziouziou I, Touzani AM, Lahlou L, **Shariat SF**, Sanguedolce F, Neuzillet Y, Ajdi F, Khabbal Y.Nutr Cancer. 2020 Nov 5:1-8. doi: 10.1080/01635581.2020.1841250. Online ahead of print.
PMID: 33148052
15. Impact of Smoking Habit on Perioperative Morbidity in Patients Treated with Radical Cystectomy for Urothelial Bladder Cancer: A Systematic Review and Meta-analysis.
Tellini R, Mari A, Muto G, Cacciamani GE, Ferro M, **Stangl-Kremser J**, Campi R, **Soria F**, Rink M, Xylinas E, Minervini A, Briganti A, Montorsi F, Roupret M, **Shariat SF**, Moschini M; European Association of Urology–Young Academic Urologists Urothelial Carcinoma Working Group (EAU-YAU).Eur Urol Oncol. 2020 Nov 4:S2588-9311(20)30171-1. doi: 10.1016/j.euo.2020.10.006. Online ahead of print.
PMID: 33160975
16. Nocebo Response in the Pharmacological Management of Overactive Bladder: A Systematic Review and Meta-analysis.
Mostafaei H, Mori K, Quhal F, Miura N, Motlagh RS, Pradere B, Laukhtina E, Lysenko I, Ghaffari S, Hajebrahimi S, Shariat SF.Eur Urol Focus. 2020 Nov 2:S2405-4569(20)30294-7. doi: 10.1016/j.euf.2020.10.010. Online ahead of print.
PMID: 33153953
17. Carcinome à cellules claires métastatique : la radiomique comme biomarqueur prédictif de la survie des patients traités par nivolumab.
Khene Z, Brassier M, Kokorian R, Mathieu R, Peyronnet B, Gasmi A, Rioux-Leclercq N, Kammerer-Jacquet S, **Shariat S, Pradere B**, Laguerre B, Bensalah K.Prog Urol. 2020 Nov;30(13):818. doi:

10.1016/j.purol.2020.07.208.

PMID: 33157774

18. Prédire la morbidité de la néphrectomie partielle : retour à la simplicité.
Mazouin C, Khene Z, Peyronnet B, Gasmi A, Dosin G, Brassier M, Thi Dang V, Ouzaid I, Larcher A, Roumiguié M, Verhoest G, **Pradère B, Shariat S**, Mathieu R, Bigot P, Doumerc N, Bensalah K. *Prog Urol.* 2020 Nov;30(13):748-749. doi: 10.1016/j.purol.2020.07.096.
PMID: 33157662
19. A review of thulium-fiber laser in stone lithotripsy and soft tissue surgery.
Enikeev D, Traxer O, Taratkin M, Okhunov Z, **Shariat S**. *Curr Opin Urol.* 2020 Nov;30(6):853-860.
doi: 10.1097/MOU.0000000000000815.
PMID: 32925311
20. Pathomics in urology.
Schuetfort VM, Pradere B, Rink M, Comperat E, **Shariat SF**. *Curr Opin Urol.* 2020 Nov;30(6):823-831. doi: 10.1097/MOU.0000000000000813.
PMID: 32881725
21. Thyroid and androgen receptor signaling are antagonized by μ -Crystallin in prostate cancer.
Aksoy O, Pencik J, Hartenbach M, Moazzami AA, Schleder M, Balber T, Varady A, Philippe C, Baltzer PA, Mazumder B, Whitchurch JB, Roberts CJ, Haitel A, Herac M, Susani M, Mitterhauser M, Marculescu R, **Stangl-Kremser J, Hassler MR, Kramer G, Shariat SF**, Turner SD, Tichy B, Oppelt J, Pospisilova S, Hartenbach S, Tangermann S, Egger G, Neubauer HA, Moriggl R, Culig Z, Greiner G, Hoermann G, Hacker M, Heery DM, Merkel O, Kenner L. *Int J Cancer.* 2021 Feb 1;148(3):731-747. doi: 10.1002/ijc.33332. Epub 2020 Oct 31.
PMID: 33034050
22. Prediction of response and survival after standardized treatment with 7400 MBq ^{177}Lu -PSMA-617 every 4 weeks in patients with metastatic castration-resistant prostate cancer.
Rasul S, Hartenbach M, Wollenweber T, Kretschmer-Chott E, **Grubmüller B, Kramer G, Shariat S**, Wadsak W, Mitterhauser M, Pichler V, Vranka C, Hacker M, Haug AR. *Eur J Nucl Med Mol Imaging.* 2020 Oct 30. doi: 10.1007/s00259-020-05082-5. Online ahead of print.
PMID: 33128131
23. Value of tumour-infiltrating immune cells in predicting response to intravesical BCG in patients with non-muscle-invasive bladder cancer: a systematic review and meta-analysis.
Kardoust Parizi M, **Shariat SF**, Margulis V, **Mori K**, Lotan Y. *BJU Int.* 2020 Oct 18. doi: 10.1111/bju.15276. Online ahead of print.
PMID: 33073457
24. Pre-therapy serum albumin-to-globulin ratio in patients treated with neoadjuvant chemotherapy and radical nephroureterectomy for upper tract urothelial carcinoma.
Pradere B, D'Andrea D, Schuetfort VM, Foerster B, Quhal F, Mori K, Abufaraj M, Margulis V, Deuker M, Briganti A, Muilwijk T, Hendricksen K, Lotan Y, Karakiewicz P, **F Shariat S**; UTUC collaboration. *World J Urol.* 2020 Oct 16. doi: 10.1007/s00345-020-03479-3. Online ahead of print.
PMID: 33067726

25. Diagnostic challenges and treatment strategies in the management of upper-tract urothelial carcinoma.
Schuetfort VM, Pradere B, Quhal F, Mostafaei H, Laukhtina E, Mori K, Motlagh RS, Rink M, D'Andrea D, Abufaraj M, Karakiewicz PI, **Shariat SF.** Turk J Urol. 2020 Oct 9. doi: 10.5152/tud.2020.20392. Online ahead of print.
PMID: 33052841
26. The prognostic value of serum MMP-7 levels in prostate cancer patients who received docetaxel, abiraterone, or enzalutamide therapy.
Szarvas T, Csizmarik A, Váradi M, Fazekas T, Hüttl A, Nyirády P, Hadaschik B, Grünwald V, Tschirdewahn S, **Shariat SF,** Sevcenco S, Maj-Hes A, **Kramer G.** Urol Oncol. 2020 Oct 9:S1078-1439(20)30436-1. doi: 10.1016/j.urolonc.2020.09.005. Online ahead of print.
PMID: 33046366
27. The effect of sex on disease stage and survival after radical cystectomy: a population-based analysis.
Rosiello G, Palumbo C, Pecoraro A, Luzzago S, Deuker M, Stolzenbach LF, Tian Z, Gallina A, Gandaglia G, Montorsi F, **Shariat SF,** Saad F, Briganti A, Karakiewicz PI. Urol Oncol. 2020 Oct 6:S1078-1439(20)30435-X. doi: 10.1016/j.urolonc.2020.09.004. Online ahead of print.
PMID: 33036900
28. Prediction of the Need for an Extended Lymphadenectomy at the Time of Radical Cystectomy in Patients with Bladder Cancer.
Moschini M, Afferi L, Gandaglia G, **D'Andrea D,** Zamboni S, Di Bona C, Mordasini L, Mattei A, Baumeister P, Martini A, Burgio G, **Shariat SF,** Sanchez-Salas R, Cathelineau X, Stabile A, Zaffuto E, Salonia A, Colombo R, Necchi A, Montorsi F, Briganti A, Gallina A. Eur Urol Focus. 2020 Oct 2:S2405-4569(20)30268-6. doi: 10.1016/j.euf.2020.09.009. Online ahead of print.
PMID: 33020030
29. Diagnostic and methodological evaluation of studies on the urinary shedding of SARS-CoV-2, compared to stool and serum: A systematic review and meta-analysis.
Roshandel MR, Nateqi M, Lak R, Aavani P, **Sari Motlagh R, F Shariat S,** Aghaei Badr T, Sfakianos J, Kaplan SA, Tewari AK. Cell Mol Biol (Noisy-le-grand). 2020 Sep 30;66(6):148-156.
PMID: 33040802
30. Incidence and outcome of salvage cystectomy after bladder sparing therapy for muscle invasive bladder cancer: a systematic review and meta-analysis.
Schuetfort VM, Pradere B, Quhal F, Mostafaei H, Laukhtina E, Mori K, Sari Motlagh R, Fisch M, **D'Andrea D,** Rink M, Gontero P, **Soria F, Shariat SF.** World J Urol. 2020 Sep 29. doi: 10.1007/s00345-020-03436-0. Online ahead of print.
PMID: 32995918
31. Differential impact of radiation therapy after radical prostatectomy on recurrence patterns: an assessment using [⁶⁸Ga]Ga-PSMA ligand PET/CT(MRI).
Grubmüller B, Jahrreiss V, Huebner N, Mitterhauser M, **Stangl-Kremser J,** Grubmüller KH, Baltzer P, Hacker M, Goldner G, **Shariat SF,** Rasul S. Prostate Cancer Prostatic Dis. 2020 Sep 29. doi: 10.1038/s41391-020-00294-0. Online ahead of print.
PMID: 32994534

32. Prognostic value of preoperative albumin to globulin ratio in patients treated with salvage radical prostatectomy for radiation recurrent prostate cancer.
Qahal F, Pradere B, Sari Motlagh R, Mori K, Laukhtina E, Aydh A, Mostafaei H, Lysenko I, Schuettfort VM, Stolzenbach F, Palumbo C, Heidenreich A, Briganti A, Karakiewicz PI, Chlosta P, **Shariat SF.** *Minerva Urol Nefrol.* 2020 Sep 29. doi: 10.23736/S0393-2249.20.03938-7. Online ahead of print.
PMID: 32993278
33. Comparative effectiveness of neoadjuvant chemotherapy in bladder and upper urinary tract urothelial carcinoma.
D'Andrea D, Matin S, Black PC, Petros FG, Zargar H, Dinney CP, Cookson MS, Kassouf W, Dall'Era MA, McGrath JS, Wright JL, Thorpe AC, Morgan TM, Holzbeierlein JM, Bivalacqua TJ, Sridhar SS, North S, Barocas DA, Lotan Y, Stephenson AJ, van Rhijn BW, Spiess PE, Daneshmand S, **Shariat SF.** *BJU Int.* 2020 Sep 27. doi: 10.1111/bju.15253. Online ahead of print.
PMID: 32981193
34. Association of preoperative serum De Ritis ratio with oncological outcomes in patients treated with cytoreductive nephrectomy for metastatic renal cell carcinoma.
Laukhtina E, Pradere B, D Andrea D, Rosiello G, Luzzago S, Pecoraro A, Palumbo C, Knipper S, Karakiewicz PI, Margulis V, **Qahal F, Sari Motlagh R, Mostafaei H, Mori K, Kimura S,** Enikeev D, **Shariat SF.** *Urol Oncol.* 2020 Dec;38(12):936.e7-936.e14. doi: 10.1016/j.urolonc.2020.08.013. Epub 2020 Sep 19.
PMID: 32962909
35. The Performance of Tumor Size as Risk Stratification Parameter in Upper Tract Urothelial Carcinoma (UTUC).
Foerster B, Abufaraj M, Mari A, Seisen T, Bandini M, Schweitzer D, Czech AK, Moschini M, **D'Andrea D,** Bianchi M, Hendricksen K, Rouprêt M, Briganti A, van Rhijn BWG, Chłosta P, Colin P, John H, **Shariat SF.** *Clin Genitourin Cancer.* 2020 Sep 18:S1558-7673(20)30218-4. doi: 10.1016/j.clgc.2020.09.002. Online ahead of print.
PMID: 33046411
36. Intraoperative aerosol viral transmission in minimally invasive surgery: a scoping review and impact on clinical guidelines and practice during the onset of the coronavirus disease 2019 (COVID-19) pandemic.
Mun DH, Pradere B, Shariat SF, Remzi M. *BJU Int.* 2020 Sep 16. doi: 10.1111/bju.15247. Online ahead of print.
PMID: 32937006